Cargando…
Real-Life Effectiveness of Vismodegib in Patients with Metastatic and Advanced Basal Cell Carcinoma: Characterization of Adverse Events and Assessment of Health-Related Quality of Life using the Dermatology Life Quality Index (DLQI) Test
INTRODUCTION: Non-melanoma skin cancer (NMSC) is the most common type of human tumor, with an estimated five million new cases each year. NMSC has been described as having a major impact on the health-related quality of life of the patient. Vismodegib is a hedgehog pathway inhibitor therapy for pati...
Autores principales: | Villani, Alessia, Fabbrocini, Gabriella, Cappello, Milena, Costa, Claudia, Scalvenzi, Massimiliano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704212/ https://www.ncbi.nlm.nih.gov/pubmed/31165365 http://dx.doi.org/10.1007/s13555-019-0303-4 |
Ejemplares similares
-
Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI)
por: Villani, Alessia, et al.
Publicado: (2019) -
Vismodegib treatment in advanced basal cell carcinomas: Real‐life experience
por: Villani, Alessia, et al.
Publicado: (2021) -
Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity
por: Scalvenzi, Massimiliano, et al.
Publicado: (2020) -
Reflectance Confocal Microscopy Identification of Subclinical Basal Cell Carcinoma after Vismodegib Treatment: Report of a Case
por: Villani, Alessia, et al.
Publicado: (2021) -
Rasch analysis holds no brief for the use of the Dermatology Life Quality Index (DLQI) in Chinese neurodermatitis patients
por: Liu, Yale, et al.
Publicado: (2016)